Gilead top of the drops as half of pharma companies see market cap growth in the third quarter

27 November 2020

A frequently expressed view on the pharma industry in 2020 is that it has offered good opportunities for investors during a difficult year for markets, partly because of the novel coronavirus pandemic reminding the world of the value of health and medicine to successful societies.

But the third quarter of the year brought very mixed share price performances for the top 20 drugmakers, with even some companies developing COVID-19 therapeutics and vaccines seeing their market capitalization (Mcap) drop.

The overall performance compares unfavorably with the quarter ending in June, in which all of the top players reported an increase in their MCap.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK